Kornimate/medical-research-clean huggingface dataset:
red grape polyphenol oral administration to women affected by nickel-mediated allergic contact dermatitis

Conditions: Allergic Contact Dermatitis

Summary: nickel (ni)-mediated allergic contact dermatitis (acd) is a very common disease worldwide. our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (nero di troia cultivar), to peripheral lymphomonocytes from ni-mediated acd patients could reduce release of t helper (h)1 \[interferon (ifn)-\] and th2 \[interleukin (il)-4\] cytokines, on the one hand. on the other hand, il-10 (an anti-inflammatory cytokine) levels increased with a reduction of il-17 (an inflammatory cytokine). also levels of nitric oxide (no) decreased in response to polyphenol pretreatment.

nickel (ni) is a transitional metal largely distributed in the environment whose continuous exposure is able to provoke local and systemic allergic contact dermatitis (acd). ni-mediated acd is characterized by loss of epidermal integrity, urticaria/angioedema, flares, and itching, whose extent depends on many variables such as genetic, time of sensitization and environmental exposure.the aim of the present research is to verify whether the oral administration of polyphenols (natur-ox®) to patients with ni-mediated acd is able to modify immune parameters.

Eligibility criteria:
inclusion criteria: * female patient; age: 25-60 years; ni-mediated acd (positive reaction to the nickel patch test) exclusion criteria: * absence of other pathologies such as immune-mediated diseases, metabolic diseases (diabetes and obesity) * infectious episodes in the last month and intake of immunosuppressive drugs or drugs influencing the immune response.

Keywords: allergic contact dermatitis cytokines cellular and molecular rehabilitation immune response nickel polyphenols
membrane shedding during severe sepsis and septic shock: pathophysiological and clinical relevance

Conditions: Severe Sepsis and Septic Shock

Summary: microparticules (mps) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. mps are know recognized as a pool of bioactive messengers with merging role in pathophysiology of immune and cardiovascular diseases. mps have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. this a prospective observational study of circulating mps and blood coagulation in septic shock patients admitted in medical intensive care units (icus) of four tertiary hospitals at baseline (d1, d2, d3, d4, d7).


Eligibility criteria:
inclusion criteria: * septic shock (patients) * without septic shock (control) * informed consent exclusion criteria: * class iv heart failure * child-plugh grade c cirrhosis * cancer under active treatment * bmi\>35kg/m2 * moribund patient * dnr decision
gemcitabine and z650 in treating patients with metastatic or recurrent pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this phase ib trial is studying how well giving gemcitabine together with z650 works in treating patients with metastatic or recurrent pancreatic cancer.

this phase ib trial is studying how well giving gemcitabine together with z650 works in treating patients with metastatic or recurrent pancreatic cancer.this phase ib trial is multi-center and open。

Eligibility criteria:
inclusion criteria: 18 ≤ age ≤ 75 years old, male or female is not limited; eastern cooperative oncology group (ecog) performance status (ps) 0 or 1 life expectancy of ≥ 12 weeks pathologically confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally recurrent, or metastatic disease. exclusion criteria: adjuvant treatment with gemcitabine within 6 months prior to the first dose; radiotherapy and anti-cancer chinese patent medicine treatment were performed within 4 weeks before the first dose; gastrointestinal diseases that could affect the absorption of z650, (e.g., serious swallowing obstruction, chronic diarrhea, bowel obstruction); doppler ultrasound evaluation of left ventricular ejection fraction \< 50%
study of antioxidants on prostate tumors in men undergoing radical prostatectomy for prostate cancer

Conditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms

Summary: the purpose of this study is to see if an intervention of antioxidants(vitamin e, selenium and lycopene) can change (reduce) prostate tumor size and alter certain markers that can affect tumor growth and prostate cancer aggressiveness.


Eligibility criteria:
inclusion criteria: * diagnosis of a gleason score \> or = to 7 adenocarcinoma of the prostate * at least 30% of one core involved * radical prostatectomy planned * willingness to discontinue use of supplements at least 4 weeks prior to study intervention (for subjects using vitamin e, selenium or lycopene at time of consent) * ability and willingness to consume study intervention for 6 - 8 weeks prior to radical prostatectomy. exclusion criteria: * previous treatment for prostate cancer * current use of finasteride or dutasteride

Keywords: male urogenital diseases antioxidants vitamin e vitamin d lycopene selenium
sympathetic nerve activity in renal failure

Conditions: Chronic Kidney Disease; Hypertension

Summary: the primary purpose is to assess the role of sympathetic activation for the development and progression of chronic renal failure. using microneurography sympathetic activity will be registered in various stages of kidney affection or failure and hypertension. a sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease. the effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.


Eligibility criteria:
inclusion criteria: * chronic renal failure stages i-iv exclusion criteria: * pregnancy and lactation * severe heart failure or ischemic heart disease * patients with nyha iii-iv

Keywords: sympatholytic treatment sympathetic nerve activity
treatment of n-methyl-d-aspartate (nmda) enhancers for schizophrenia

Conditions: Schizophrenia

Summary: hypofunction of n-methyl-d-aspartate (nmda) receptor has been implicated in the pathophysiology of schizophrenia. to date, several reported trials on adjuvant nmda-enhancing agents, including glycine and sarcosine (a glycine transporter i inhibitor), demonstrated clinical benefits for schizophrenia patients. this project aims to compare the efficacy and safety of sarcosine and combination of sarcosine and be, as adjunctive therapy for schizophrenia, and to explore the possible synergistic effects of them. sixty chronic schizophrenic inpatients will be enrolled in the 12-week double-blind, placebo-controlled trial. the participants receive stable antipsychotic regimens concomitant with sarcosine (2 g/d) (n=21), sarcosine(2 g/d) + be(1 g/d ) (n=21), and placebo(n=21). measures of clinical efficacy and side-effects were determined every 3 weeks. measures of cognitive function were determined at the beginning and the end of the study. the efficacies of three groups are compared, and the characteristics of better responders are analyzed.

we will measure clinical efficacy every 3 weeks during the treatment. at the beginning and the end of the trial,we will utilize a battery of tests to assess the effect of the treatment on cognitive functions.the side effect assessments are also performed every 3 weeks. side effect assessments include simpson-angus rating scale for extrapyramidal side-effects, abnormal involuntary movement scale (aims) for dyskinesia, and barnes akathisia scale. systemic side effects are reviewed by applying the udvalg for kliniske undersogelser (uku) side-effects rating scale. daao level, routine laboratory tests, including cbc, biochemistry , urine analysis, and ekg, will be checked at baseline and the end of week 12. to compare the metabolic syndrome parameters among groups, body mass index, hip size, waist size, blood pressure, fasting blood sugar, triglyceride, and total-cholesterol will be checked at baseline and the end of the study.

Eligibility criteria:
inclusion criteria: * the participants fulfill the criteria of schizophrenia according to the * diagnostic and statistic manual, fourth edition (dsm-iv). * the participants remain stable schizophrenic symptoms and receive stable antipsychotic regimens at last 8 weeks before enrollment. * the participants agree to participate in the study and provide informed consent. exclusion criteria: * history of alcohol or substance dependence, history of epilepsy, head trauma or cns diseases, history of major, untreated medical diseases, mental retardation, pregnancy or lactation

Keywords: schizophrenia cognitive function n-methyl-d-aspartate receptor
analgesic effect of bilateral quadratus lumborum block in the end of colorectal laparosopic surgery.

Conditions: Post Operative Pain; Laparoscopic Colorectal Surgery

Summary: the primary purpose of coloqual study is to demonstrate the superiority of analgesic effect of a bilateral quadratus lumborum block (qlb), performed at the end of laparoscopic colorectal surgery, compared to standard of care. the investigators hypothesized that a bilateral quadratus lumborum block performed at the end of laparoscopic colorectal surgery would reduce the incidence of post operative pain, time spent in recovery room, improve patient's satisfaction, and reduce hospitalisation time

visits: * the patient will arrive in the department the day before the surgical intervention (day-1). during this preoperative visit (day-1), the investigator * will preselect potentially eligible patients * will offer to participate to this study * will give the notice form to the patients * will present the research: objectives, benefits and constraints for the patients * the intervention day (day 0): the investigator will collect the signed consent form after having ascertained the understanding of the notice form by the patient and checking the inclusion and non-inclusion criteria. the randomization will be done via the ecrf module (allocation group and number) and the preoperative data registration in the ecrf. surgical intervention (day 1): all patients will receive standard anaesthesia using sufentanyl, propopol, cisatracurium and sevoflurane. prevention of nausea and vomiting is performing using apfel score. anti microbial prophylaxis is performed according recommendations. all patients will receive post operative multimodal analgesia using intravenous lidocaine, acetaminophene, ketaminophene, and morphine if nrs (numerating rating scale) \> 3 at the end of the surgery, patients in the experimental group will receive a bilateral ultrasound guided quadratus lumborum block with 15 ml of 3,75 mg/mg of ropivacaine. patients in the control group will not receive the block

Eligibility criteria:
inclusion criteria: * age \> 18 years old * patients operated of a scheduled laparoscopic colorectal surgery * patients having given consent in the mannen described in article l1122-1-1 of the public health code * patients affiliated with asocial security regimen or beneficiary of such a regimen exclusion criteria: * renal insufficiency (ie glomerular filtration output \< 35 ml/min) * patients with chronic inflammatory bowel disease * body mass index \> 35 kg/m2 * chronic pain with opiates * patients with cognitive troubles * coagulation disorders (platelets count \< 80g/l, pt\< 50%, v factor \< 50%) * pregnancy * breastfeeding * local anesthesics (amide class) allergy * laparotomy conversion

Keywords: prospective randomized pilot study quadratus lumborum block quo r 40 score post operative pain
preemptive tips for gastric variceal bleeding in patients with cirrhosis

Conditions: Portal Hypertension; Gastric Varices Bleeding; Portosystemic Shunt

Summary: the prevalence of gastric varices is approximately 20%. it is important to note that gastric varices tend to bleed more severely, have a higher morbidity and mortality rate, and have a 35% to 90% risk of rebleeding after the cessation of acute hemorrhage. because of the relatively low prevalence of gastric varices, the existing clinical studies have many deficiencies, and there is much controversy in the academic community, the optimal treatment and prevention strategies for gastric varices have not yet been fully defined. in the last few years, important advances have been made in the treatment and prevention of gastric variceal bleeding in patients with cirrhosis. experts agree that the combination of pharmacological and endoscopic injection of tissue adhesives should be the first line of therapy in the acute bleeding episode from isolated gastric varices (igv1) or type 2 gastroesophageal varices (gov2) varices; whereas transjugular intrahepatic portosystemic shunt (tips) is considered a rescue therapy. tips has been shown to effectively prevent variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy and/or liver failure. in this sense, a recent randomized controlled trial (rct) in fundal variceal bleeding showed that an early tips, performed during the first 5 days after patient admission resulted in a significant decrease in failure to control bleeding and early and late rebleeding. however, the study was conducted for 4 years and only included 25 patients. due to insufficient sample size, it was unable to reflect whether priority tips can bring survival benefits to patients with gastric variceal bleeding. therefore, there is an urgent need for multi-center clinical studies with large samples to provide high-quality evidence in the field of prioritizing tips for the treatment of acute gastric variceal bleeding. the present study aims to compare the preemptive tips (performed during the first 72 hours after endoscopy) with standard second prophylaxis (endoscopic injection of tissue adhesives plus carvedilol) for patients with acute bleeding from gastric varices (igv1 or gov2). the primary outcome will be a 6-week mortality from inclusion.


Eligibility criteria:
inclusion criteria: * cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy); * admission due to acute bleeding from gastric varices (igv1 or gov2). exclusion criteria: * prior treatment with tips or surgical shunt; * presence of contraindications to endoscopic treatment, carvedilol, or tips; * presence of hepatocellular carcinoma exceeding milan criteria; * presence of other systemic malignant tumors with expected survival time not exceeding 6 months; * presence of uncontrollable infection or sepsis; * presence of cardiac, pulmonary, or renal failure; * pregnant or lactating women; * refusal to sign the informed consent form.
a prospective multi-center phase iii randomized controlled trial

Conditions: Carcinoma，Non-Small-Cell Lung

Summary: the purpose of this study is to investigate the pfs, orr, os and overall toxicity value（otv）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.


Eligibility criteria:
inclusion criteria: 1. patient who was confirmed primary adenocarcinoma by pathologic histology or cytology 2. the tnm staging system according to iaslc2009 was stageiv or those stageiiib who were not fit for operation or radiotherapy 3. including one available evaluation lesion at least according to recist criteria 4. adult patients (≥18 years and ≤75 years). ecog performance status 0 or 1 .life expectancy of at least 12 weeks.haemoglobin ≥90g/dl, absolute neutrophil count (anc)≥ 2x 109/l, platelets ≥100 x 109/l. total bilirubin ≤upper limit of normal (uln). alt and ast ≤ 2.5 x uln. creatinine clearance ≥60ml/min (calculated according to cockcroft-gault formula). 5. patients who had never received any antineoplastic therapy exclusion criteria: 1. patient who has another cancer in recent 5 years,not including basal cell carcinoma or cervical carcinoma in situ 2. patient with brain metastases whose intracranial pressure symptoms can not control by using glucocorticoid or mannitol 3. previous radiotherapy（palliative radiotherapy in order to pain management can be excluded） 4. patient who has used chemotherapy before(bisphosphonate can be excluded ) 5. serious uncontrolled systemic disease including active infection,uncontrolled hypertension,diabetes,unstable angina,congestive heart failure,myocardial infarction,severe arrhythmia which needs drugs,hepatic、renal and metabolic disease 6. patient who is allergic to drugs we need to use 7. patients who are in pregnancy or lactation 8. ast or alt 》2.5 \* upper limit of normal (uln)，and alp》5\*uln

Keywords: non-small-cell lung cancer overall toxicity value
optimizing postpartum pelvic health through self-scar tissue massage of episiotomy and perineal scar tissue a pilot rct

Conditions: Episiotomy; Complications; Scar Tissue; Perineal Tear; Vaginal Tear Resulting From Childbirth

Summary: the goal of this pilot randomized control trial (rct) is to determine if a larger rct evaluating the effect of self-scar tissue massage of episiotomy and/or vagina/perineal tear scar tissue on pelvic health outcomes is feasible. the main questions it aims to answer are: can the investigators recruit 130 participants and aim for 80% retention of participants in this study? are the response rates to questionnaires and completeness of questionnaires acceptable? do the participants find the self-scar tissue massage intervention easy and acceptable to perform and do they adhere to the protocol? type of study: clinical trial participant population/health conditions: the participant population will be 18 years of age or older, primiparous, within 1 year postpartum after vaginal delivery with healed episiotomy and/or vaginal perineal tear(s) as confirmed to them by their maternity care provider or family doctor at their 6 week postpartum check or other appointment. the participants will also need to have sufficient proficiency in english to understand intervention instructional video and complete written questionnaires. investigators will compare the scores on two reliable and validated pelvic health questionnaires in those in the intervention and control groups. the intervention group will be provided an instructional video on self-scar tissue massage and asked to perform self-scar massage and record their intervention and experience over a 6-week period. the control group will receive routine postnatal care (no self-scar massage training or performance). patient medical records will be used to collect demographic data and labour and delivery characteristics. two reliable and validated pelvic health questionnaires will be used for outcome measures. baseline outcomes will be performed at the start of the study and then repeated 6 weeks later and again 18 weeks later.


Eligibility criteria:
inclusion criteria: * age ≥18 years * primiparous * within 1 year postpartum after vaginal delivery with episiotomy and/or vaginal/perineal tear * healed episiotomy and/or vagina/perineal tear as confirmed to them by their maternity care provider or family doctor at their postpartum check or other appointment * sufficient proficiency in english to understand intervention instructional video and complete written questionnaires. exclusion criteria: * self-reported current vaginal infection or urinary tract infection * self-reported gynecological surgery after delivery

Keywords: perineal tear vaginal tear episiotomy
comparing 6-minute walk tests for ambulatory oxygen assessment

Conditions: Respiratory Disease

Summary: patients with lung disease who report breathlessness on exertion are often referred for a 6mwt. due to the nature of the 6mwt (hereon referred to as a max-6mwt), patients are required to walk as far as they can in 6 minutes. this may lead to an inaccurate assessment of their requirement for ambulatory oxygen as this form of exercise may not correspond to their normal daily activities. in this study, patients who are routinely referred for a max-6mwt to investigate possible exercise-induced hypoxaemia will be invited to perform an additional walking test which is performed at their normal walking speed, referred here on in as a nor_6mwt. we hypothesise that performing a nor_6mwt will provide a more accurate assessment of a patients' oxygen requirement, primarily from their oxygen desaturation during the test.

patients with lung disease who report breathlessness on exertion are often referred for a 6mwt. during this test patients are asked to walk up and down a corridor (or other flat area) for six minutes whilst their blood oxygen levels and heart rate are non-invasively measured using a pulse oximeter (finger probe) and the distance walked is measured. in addition, a questionnaire that obtains a borg score measures the patients perceived breathlessness and leg muscle fatigue both before and immediately following the test. due to the nature of the 6mwt (hereon referred to as a max-6mwt), patients are required to walk as far as they can in 6 minutes. this may lead to an inaccurate assessment of their requirement for ambulatory oxygen as this form of exercise may not correspond to their normal daily activities. it may also not accurately measure the normal changes in oxygen saturation (or desaturation) that occurs in these patients during their normal daily activities (such as walking to the shops, walking up the stairs, gardening). in this study, patients who are routinely referred for a max-6mwt to investigate possible exercise-induced hypoxaemia will be invited to perform an additional walking test which is performed at their normal walking speed, referred here on in as a nor_6mwt. we hypothesise that performing a nor_6mwt will provide a more accurate assessment of a patients' oxygen requirement, primarily from their oxygen desaturation during the test.

Eligibility criteria:
inclusion criteria: * referred for a standard 6-minute walk test * has the capacity to give informed consent * is aged between 18 and 90 exclusion criteria: * lack of capacity to provide informed consent * poor peripheral perfusion that prevents an accurate measurement of spo2 * contraindicated to perform a max_6mwt as indicated in the standard hhft 6mwt so
evaluation of reliability of the near-infrared imaging system (vistacam ix proxi) in comparison with digital radiographic findings and icdas-ii in detection of approximal carious lesions.

Conditions: Proximal Dental Caries

Summary: the aim of this study is to evaluate the clinical performance of the near-infrared imaging system vistacam ix proxi in comparison with digital radiographic findings and icdas-ii in detection of approximal carious lesions.


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 40 years. * no gender restriction. * patients should have an acceptable oral hygiene level. * patients must have at least one posterior proximal caries exclusion criteria: * patients with a compromised medical history. * severe or active periodontal disease. * heavy bruxism or a traumatic occlusion. * acute or chronic dental infection. * pregnant or breastfeeding women. * patients with posterior restorations on molars or premolars
preemptive local anesthesia in vaginal surgery

Conditions: Pain, Postoperative

Summary: preemptive analgesia is an intervention which provides an anesthetic prior to initiating a painful stimulus. this trial is examining the effects of a local anesthetic given at the point of innervation prior to performing a vaginal hysterectomy with suspension sutures.


Eligibility criteria:
inclusion criteria: * women undergoing vaginal hysterectomy with mccall's culdoplasty

Keywords: preemptive analgesia paracervical block vaginal hysterectomy